Sector ratings BeiGene, Ltd.

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 20/09/2024 am IST			5-day change	1st Jan Change
198.59 ^USD	+0.66%		+1.18%	+10.11%

18/09	JMP Securities Initiates BeiGene at Outperform With $288 Price Target	MT
17/09	BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma After Prior Chemotherapy	CI

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	ESG Refinitiv	Capi. ($)
BEIGENE, LTD.	-	B	21B
VERTEX PHARMACEUTICALS INCORPORATED		B+	124B
REGENERON PHARMACEUTICALS, INC.		B+	124B
ARGENX SE	-	B	31.62B
BIONTECH SE	-	B+	29.65B
GENMAB A/S		A-	16.66B
WUXI APPTEC CO., LTD.		A-	16.12B
INSMED INCORPORATED	-	C	12.59B
NEUROCRINE BIOSCIENCES, INC.		C+	12.35B
SAREPTA THERAPEUTICS, INC.		C+	11.99B
ZEALAND PHARMA A/S	-	B	9.47B
LEGEND BIOTECH CORPORATION	-	D	9.37B
ASCENDIS PHARMA A/S	-	C+	8.41B
AKESO, INC.	-	B-	8.02B
EXELIXIS, INC.		B	7.87B
HALOZYME THERAPEUTICS, INC.		A-	7.85B
PHARMAESSENTIA CORPORATION		-	7.26B
Average		B	26.95B
Weighted average by Cap.		B